SCHEMBL30749066

SCHEMBL30749066

OCc1ncc2c(n1)N(c1ccc(OC3CCOCC3)cc1)CC21CC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 1/20 0.34
P2RX3 P56373 1/20 0.33
APP P05067 1/20 0.33
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
FGFR3 P22607 1/20 0.32
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32
PDE1C Q14123 1/20 0.32
AXL P30530 1/20 0.32
TYRO3 Q06418 1/20 0.32
MERTK Q12866 1/20 0.32
PDE4B Q07343 1/20 0.31
USP1 O94782 1/20 0.31
CPT2 P23786 1/20 0.31
CPT1A P50416 1/20 0.31
DHFR P00374 1/20 0.31
CHEK1 O14757 1/20 0.31
GRM5 P41594 1/20 0.31
TRPV4 Q9HBA0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749012 0.90 PDE4B (0.40) CHRM4FGFR1FGFR2FGFR3PDE4B
SCHEMBL30748796 0.89 CHRM4 (0.33) CHRM4P2RX3PIK3CDPIK3CA
SCHEMBL31691440 0.85 PTPN11 (0.34) P2RX3APPFGFR1FGFR2FGFR3
SCHEMBL31691272 0.85 PDE1A (0.31) PDE1APDE1BPDE1CAXLTYRO3
SCHEMBL30748808 0.82 AXL (0.31) AXLTYRO3MERTKTRPV4
SCHEMBL30749034 0.76 ALDH1A1 (0.45) PIK3CA
SCHEMBL31691212 0.75 PDE4B (0.37) PDE4BCPT2CPT1APIK3CD
SCHEMBL30749019 0.74 PDE4B (0.40) PDE4BCPT2CPT1ADHFRCHEK1
SCHEMBL31691262 0.74 PDE10A (0.31)
SCHEMBL30749104 0.71 PDE4B (0.43) PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT CHRM4 4607/4885P2RX3 1730/4885APP 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.